SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Gliatech (GLIA)

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: WTDEC who wrote (1159)1/8/2000 1:01:00 AM
From: scaram(o)uche  Read Replies (1) of 2001
 
Walter:

The company is trying to get too much done, given the number of people to do it......... a very well-meaning, sincere and capable crew that is stretched too thin.

This has resulted in lots of leverage.... productivity with relatively little burn. There comes a time in a business plan, however, where a bit more vision -- and eye for potential -- makes a big difference. If you go beyond that point with same thin crew, as you know, you allow competitors to move on territory that could have been yours.

No, I don't think that we're riding the wrong pony. However, it is time to transition from an 80's biotech vision to the here and now. It was time eighteen months ago, unfortunately.

>> Should have shown a bit more life on a day like today. <<

One can sit there with level II and virtually watch the way the shorts are working it down. They (or someone) sacrifice(s) a few shares to get an uptick, and.... bang!, down comes the ask. Relentless, and they know that the company won't fight back.

Ages ago, I suggested a mini-Chiron-like deal.... a company that likes surgical products and that also has an eye for neuro. Stryker-like. I'm not talking big numbers.... one doesn't need to think grandiose when the market cap is piddly.

That's one concept. Not saying it's good, but it's a frigging concept. Would have been good to explore. Would have been nice to ask if John Brown [or CEO with vision of your choice] wanted to play a round of golf.

Since Perceptin addresses more than one (big) indication, I've also suggested licensing on the basis of geographies or indications. Do a "Taisho" for one indication, for example.

That's another concept. Not saying it's any good either, but it's a second frigging concept.

It's just an issue of lack of vision. The stock could have benefited from the influx of mucho bucks and the efflux of 2M "short" shares, but this Board just sits there on their frigging hands saying "alllee, alllee, in free!"

There are 57 hours between now and market open on Monday. They go up for biotech's biggest show, two hours after the open. In those 57 hours, I could write 10 polished, knock-your-socks off variants for each of two releases.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext